
Judgment in the Cloud: The future of risk and regulation with James Lord, Google Cloud
The Medical Device Coordination Group (“MDCG”) has issued guidance on the safe making available of medical device software (“MDSW”) apps on online platforms (MDCG 2025-4). MDCG 2025-4 outlines the regulatory roles of online platform providers under the EU Medical Devices Regulation (“MDR”) and the In Vitro Diagnostic Medical Device Regulation (“IVDR”) as well as the Digital Services Act (“DSA”) with respect to MDSW.
On 16 June 2025, the MDCG published guidance MDCG 2025-4 on the safe making available of medical device software (MDSW) apps on online platforms. This guidance seeks to clarify the obligations of app platform providers and define their regulatory roles under the EU MDR and the IVDR as well as the DSA1 with respect to MDSW.
This guidance is published amid the growing availability of health-related applications through app stores and digital marketplaces, raising concerns around safety, compliance with applicable legal requirements and transparency.
Key takeaways from MDCG 2025-4 include:
The guidance distinguishes between the regulatory roles that app platform providers might fulfil based on the activities they undertake in the supply chain of MDSW. App platform providers may act as either:
In the former case, DSA obligations apply, such as notice-and-action mechanisms for illegal content, user transparency and online interface design that allows MDSW manufacturers/app developers to comply with their respective obligations under the MDR/IVDR (e.g., information requirements). In the latter, app platform providers must ensure compliance with MDR/IVDR requirements and cooperation with competent authorities.
The guidance also clarifies that uploading of a MDSW app by a manufacturer qualifies as “placing on the market”, while the time during which the MDSW app is hosted and made available in the app platform corresponds to the “making available on the market”.
App platform providers are encouraged to clearly separate medical device apps/MDSW from lifestyle or wellness apps without an intended medical purpose. Only software that meets MDR/IVDR requirements—and for which key compliance information has been provided—should be listed under the medical device category.
App platform providers must design their platforms in a way that enables MDSW manufacturers, distributors or importers to comply with their traceability and information obligations under the MDR/IVDR, by providing the following information on the app platform:2
App platform providers must make best efforts to verify the information provided by MDSW manufacturers/distributors/importers before allowing them to offer their MDSW on their platforms,. They must also make reasonable efforts to check official online databases to verify if any listed MDSW has been flagged as illegal.3
Very Large Online Platforms, including designated app platform providers, must carry out annual risk assessments under the DSA to identify and analyse systemic risks linked to the functioning or use of their services—particularly risks related to the dissemination of illegal content, such as non-compliant MDSW—and take appropriate mitigation measures.4
Please contact our team if you have any questions.
Authored by Fabien Roy and Anastasia Vernikou.
References